Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTOR | P42345 | 20/20 | 0.67 |
| ▸ | PIK3CA | P42336 | 11/20 | 0.67 |
| ▸ | RPTOR | Q8N122 | 10/20 | 0.64 |
| ▸ | MLST8 | Q9BVC4 | 10/20 | 0.64 |
| ▸ | RICTOR | Q6R327 | 1/20 | 0.46 |
| ▸ | MAPKAP1 | Q9BPZ7 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29543307 | 0.88 | MTOR (0.74) | MTORPIK3CARPTORMLST8RICTOR | |
| SCHEMBL138496 | 0.88 | MTOR (0.74) | MTORPIK3CARPTORMLST8RICTOR | |
| SCHEMBL138501 | 0.86 | MTOR (0.80) | MTORPIK3CARPTORMLST8RICTOR | |
| SCHEMBL29543545 | 0.86 | MTOR (0.80) | MTORPIK3CARPTORMLST8RICTOR | |
| SCHEMBL136144 | 0.84 | MTOR (0.69) | MTORPIK3CARPTORMLST8RICTOR | |
| SCHEMBL29522927 | 0.84 | MTOR (0.69) | MTORPIK3CARPTORMLST8RICTOR | |
| SCHEMBL29522616 | 0.83 | MTOR (0.71) | MTORPIK3CARPTORMLST8RICTOR | |
| SCHEMBL138350 | 0.83 | MTOR (0.71) | MTORPIK3CARPTORMLST8RICTOR | |
| SCHEMBL138560 | 0.82 | MTOR (0.88) | MTORPIK3CARPTORMLST8RICTOR | |
| SCHEMBL29522104 | 0.82 | MTOR (0.88) | MTORPIK3CARPTORMLST8RICTOR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8110578-B2 | Pyrazino[2,3-b]pyrazine mTOR kinase inhibitors for oncology indications and diseases associated with the mTOR/PI3K/Akt pathway | SIGNAL PHARMACEUTICALS, LLC (US) | 2012-02-07 | — | — | US | disclosed |
| US-8110578-B2 | Pyrazino[2,3-b]pyrazine mTOR kinase inhibitors for oncology indications and diseases associated with the mTOR/PI3K/Akt pathway | SIGNAL PHARMACEUTICALS, LLC (US) | 2012-02-07 | — | — | US | disclosed |
| US-20100216781-A1 | mTOR KINASE INHIBITORS FOR ONCOLOGY INDICATIONS AND DISEASES ASSOCIATED WITH THE mTOR/PI3K/AKT PATHWAY | SIGNAL PHARMACEUTICALS, LLC | 2010-08-26 | — | — | US | disclosed |
| US-20100216781-A1 | mTOR KINASE INHIBITORS FOR ONCOLOGY INDICATIONS AND DISEASES ASSOCIATED WITH THE mTOR/PI3K/AKT PATHWAY | SIGNAL PHARMACEUTICALS, LLC | 2010-08-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100216781-A1 | mTOR KINASE INHIBITORS FOR ONCOLOGY INDICATIONS AND DISEASES ASSOCIATED WITH THE mTOR/PI3K/AKT PATHWAY | MTOR, RICTOR, RPTOR | MTOR 1/4885PIK3CA 10/4885RPTOR 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.